Valentina N. Lombardo

Dr. Valentina N. Lombardo

Medicine and Surgery, Università degli Studi di Enna Kore, Enna, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2021 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
Luca FalzoneLuca Falzone
Luca Falzone
GSGiuseppa Scandurra
Giuseppa Scandurra
Valentina N. LombardoValentina N. Lombardo
Valentina N. Lombardo
GGGiuseppe Gattuso
Giuseppe Gattuso
ALAlessandro Lavoro
Alessandro Lavoro
PSPaolo Scollo
Paolo Scollo
Ovarian cancer represents one of the most aggressive female tumors worldwide. Over the decades, the therapeutic options for the treatment of ovarian cancer have been improved significantly through the advancement of surgical techniques as well as the availability of novel effective drugs able to extend the life expectancy of patients. However, due to its clinical, biological and molecular complexity, ovarian cancer is still considered one of the most difficult tumors to manage. In this context, several studies have highlighted how a multidisciplinary approach to this pathology improves the prognosis and survival of patients with ovarian cancer. On these bases, the aim of the present review is to present recent advantages in the diagnosis, staging and treatment of ovarian cancer highlighting the benefits of a patient‑centered care approach and on the importance of a multidisciplinary team for the management of ovarian cancer.

14 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
Giuseppe BannaGiuseppe Banna
Giuseppe Banna
UBUmberto Basso
Umberto Basso
EGEmilio Francesco Giunta
Emilio Francesco Giunta
LFLucia Fratino
Lucia Fratino
SRSara Elena Rebuzzi
Sara Elena Rebuzzi
PRPasquale Rescigno
Pasquale Rescigno
Introduction: Androgen receptor pathway inhibitors (ARPIs) have been increasingly offered to older patients with prostate cancer (PC). However, prognostic factors relevant to their outcome with ARPIs are still little investigated. Methods and Materials: The Meet-URO network ADHERE was a prospective multicentre observational cohort study evaluating and monitoring adherence to ARPIs metastatic castrate-resistant PC (mCRPC) patients aged ≥70. Cox regression univariable and multivariable analyses for radiographic progression-free (rPFS) and overall survival (OS) were performed. Unsupervised median values and literature-based thresholds where available were used as cut-offs for quantitative variables. Results: Overall, 234 patients were enrolled with a median age of 78 years (73–82); 86 were treated with abiraterone (ABI) and 148 with enzalutamide (ENZ). With a median follow-up of 15.4 months (mo.), the median rPFS was 26.0 mo. (95% CI, 22.8–29.3) and OS 48.8 mo. (95% CI, 36.8–60.8). At the MVA, independent prognostic factors for both worse rPFS and OS were Geriatric G8 assessment ≤ 14 (p < 0.001 and p = 0.004) and PSA decline ≥50% (p < 0.001 for both); time to castration resistance ≥ 31 mo. and setting of treatment (i.e., post-ABI/ENZ) for rPFS only (p < 0.001 and p = 0.01, respectively); age ≥78 years for OS only (p = 0.008). Conclusions: Baseline G8 screening is recommended for mCRPC patients aged ≥70 to optimise ARPIs in vulnerable individuals, including early introduction of palliative care.

3 August 2022 in The Oncologist
Verified
Journal Article
Open access
PDF file
PRPasquale Rescigno
Pasquale Rescigno
MMMarco Maruzzo
Marco Maruzzo
SRSara Elena Rebuzzi
Sara Elena Rebuzzi
VMVeronica Murianni
Veronica Murianni
MCMarika Cinausero
Marika Cinausero
Giuseppe BannaGiuseppe Banna
Giuseppe Banna
Novel androgen receptor signaling inhibitors for prostate cancer (PC) impose the burden of self-administration on older patients overwhelmed by the requirement of many other concomitant medications. This study evaluated the proportion of non-adherence in a 12-month follow-up period and the first 3 months to abiraterone (ABI) or enzalutamide (ENZ). In a prospective multicenter observational cohort study, patients with metastatic castration-resistant PC (mCRPC) aged ≥70 years receiving ABI or ENZ pre- or post-docetaxel were enrolled. Treatment monitoring included pill counting, a self-assessment questionnaire, and clinical diaries at each clinical visit. Non-adherence rates were based on proportions of missed/prescribed pills ratios by pill counting. Overall, 234 patients were recruited with median age of 78 years (range, 73–82); 86 (37%) were treated with ABI, and 148 (63%) with ENZ. The median follow-up for adherence was seven monthly cycles (IQR: 4–12). The two cohorts were well balanced for baseline characteristics. The percentage of non-adherence by pill counting was slightly higher for ABI than ENZ (5.2% vs. 4.2%, P < .001). By self-reporting, patients on ENZ tended to report more frequently than those with ABI forgetfulness as the reason for missing events (42% vs. 17%, P < .001). A lower Geriatric G8 score correlated with non-adherence (P = .004). Overall survival (OS) was 48.8 months. Patients on ABI had radiographic progression-free survival (rPFS) of 28.4 [24.2–32.5], while for ENZ patients, we reported a median rPFS of 23.1 [18.2–28.1] months. Physicians tend to treat older mCRPC patients with ENZ. Non-adherence rate is relatively low overall but can be higher with ABI than with ENZ and correlates with the Geriatric G8 score. Forgetfulness is a potential barrier for ENZ.

21 March 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
MBMichele Bartoletti
Michele Bartoletti
Alice BergaminiAlice Bergamini
Alice Bergamini
GGGaia Giannone
Gaia Giannone
CNCamilla Nero
Camilla Nero
LMLucia Musacchio
Lucia Musacchio
SPSandro Pignata
Sandro Pignata

Verified
Journal Article
Open access
PDF file
GSGiovanni Luca Scaglione
Giovanni Luca Scaglione
SPSandro Pignata
Sandro Pignata
APAngela Pettinato
Angela Pettinato
CPCarmela Paolillo
Carmela Paolillo
DCDaniela Califano
Daniela Califano
ETTORE CAPOLUONGOETTORE CAPOLUONGO
ETTORE CAPOLUONGO
High-grade serous ovarian cancer (HGSOC) patients carrying the BRCA1/2 mutation or deficient in the homologous recombination repair system (HRD) generally benefit from treatment with PARP inhibitors. Some international recommendations suggest that BRCA1/2 genetic testing should be offered for all newly diagnosed epithelial ovarian cancer, along with HRD assessment. Academic tests (ATs) are continuously under development, in order to break down the barriers patients encounter in accessing HRD testing. Two different methods for shallow whole-genome sequencing (sWGS) were compared to the reference assay, Myriad. All these three assays were performed on 20 retrospective HGSOC samples. Moreover, HRD results were correlated with the progression-free survival rate (PFS). Both sWGS chemistries showed good correlation with each other and a complete agreement, even when compared to the Myriad score. Our academic HRD assay categorized patients as HRD-Deficient, HRM-Mild and HRN-Negative. These three groups were matched with PFS, providing interesting findings in terms of HRD scoring and months of survival. Both our sWGS assays and the Myriad test correlated with the patient’s response to treatments. Finally, our AT confirms its capability of determining HRD status, with the advantage of being faster, cheaper, and easier to carry out. Our results showed a prognostic value for the HRD score.

22 September 2022 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
MTMargherita Turinetto
Margherita Turinetto
Valentina N. LombardoValentina N. Lombardo
Valentina N. Lombardo
CPCarmela Pisano
Carmela Pisano
LMLucia Musacchio
Lucia Musacchio
SPSandro Pignata
Sandro Pignata
Endometrial cancer can be characterized by high instability of microsatellites (MSI-H), a biomarker indicative of sensibility to immune checkpoint inhibitors (ICIs). The results of the KEYNOTE-158 ...